Welcome to our dedicated page for SERNOVA news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on SERNOVA stock.
Sernova Corp. is a clinical-stage biotechnology company focused on developing therapeutic cell technologies for chronic diseases like insulin-dependent diabetes, thyroid disease, and hemophilia A. The company's lead asset, the Cell Pouch System, is an implantable medical device that creates a natural vascularized tissue environment for long-term survival of therapeutic cells. Sernova's technology aims to provide a 'functional cure' for diabetes and other chronic conditions by releasing essential factors to address deficiencies in patients' bodies. The company is also working on shielding therapeutic cells from immune system attacks and developing an off-the-shelf iPSC-based islet replacement therapy in partnership with Evotec. In addition, Sernova is progressing programs for hypothyroid disease and hemophilia A using its Cell Pouch System.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) has announced positive interim data from its ongoing Phase I/II clinical trial of the Cell Pouch Transplant System for type 1 diabetes (T1D). The trial shows sustained insulin independence in all 6 patients of Cohort A after islet transplantation. Notably, histological data from a patient's explanted Cell Pouch after 5+ years revealed abundant, well-vascularized, functioning islets producing insulin, glucagon, and somatostatin. The Cell Pouch demonstrated no evidence of fibrosis or degradation after long-term implantation. Sernova plans to complete Cohort B soon and initiate Cohort C with an optimized immune suppression regimen. The company is also developing iPSC-derived islet-like clusters with partner Evotec for a scalable cell source.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), a clinical-stage biotech company focusing on regenerative medicine cell therapies, has appointed Jonathan Rigby as its new CEO. Rigby, a type 1 diabetic himself, brings extensive experience in raising capital, leading biotech companies to Nasdaq listings, and achieving strategic acquisitions. The Board believes Rigby's leadership will position Sernova to achieve its strategic milestones.
Rigby's background includes several CEO roles and board positions in biotech companies, particularly in the diabetes field. He holds a degree in biological sciences and an MBA. The appointment aims to drive Sernova's growth and realize its full potential in developing treatments for chronic diseases, including its ongoing phase 1/2a clinical trial in type 1 diabetes.
FAQ
What is the current stock price of SERNOVA (SEOVF)?
What is the market cap of SERNOVA (SEOVF)?
What is Sernova Corp. focused on developing?
What is the Cell Pouch System developed by Sernova Corp.?
What is the goal of Sernova's technology in addressing chronic diseases?
What partnership has Sernova entered into for developing an islet replacement therapy?
What additional programs is Sernova working on using the Cell Pouch System?
How does Sernova plan to shield therapeutic cells from immune system attacks?
What is Sernova's approach to providing potentially unlimited insulin-producing cells for diabetes treatment?
What is the status of Sernova's ongoing clinical study for diabetes treatment?
Who is the research collaboration partner of Sernova in the field of Hemophilia A?
Where can one find more information about Sernova Corp.?
What recent achievement has Sernova Corp. announced related to the Cell Pouch System?
